Please log in
to access more information


User name and Password not recognised

Home Page > The Company > Management


Jan Ohrstrom Jan Ohrstrom, MD
Chief Executive Officer

Dr. Ohrstrom is a Senior Executive with international experience in Biotechnology and Pharma. He has held Management positions in Large and Mid-Cap US/EU Biopharma companies, amongst them Novo Nordisk, ZymoGenetics, ProFibrix and The Medicines Company. Dr. Ohrstrom was part of the Management Team that took ZymoGenetics public on Nasdaq, where he also spearheaded the development and approval of Recothrom. Dr. Ohrstrom incorporated ProFibrix Inc in 2008 and in 2013 as CEO led the company through an M&A with The Medicines Company. ProFibrix’s lead compound Raplixa was approved in 2015 in the US and EU. Dr. Ohrstrom is a Board member of Blaze Bioscience in Seattle and has held other board positions in private and public life science companies.

William D. Spotnitz William D. Spotnitz M.D., M.B.A.
Chief Medical Officer

Dr. Spotnitz is an international expert in the field of hemostats, sealants, and adhesives with more than 70 publications in this area of study. He has extensive experience in surgical needs assessment, device design, preclinical experimentation, clinical trials, FDA regulatory affairs, product education, and marketing to health professionals having collaborated with more than 30 different companies in these areas.

Valérie Centis Valérie Centis
Executive Vice President & Chief Scientific Officer

With a Ph.D. in Biotechnological and Chemical Engineering from Sherbrooke University and a Biomedical Science degree from the University of Montreal, Valerie Centis joined Biom'up in 2010 as a R&D and Regulatory Project Manager. As Chief Scientific Officer, she now manages FDA and EC product design in conformity with regulatory requirements, overseeing various teams and international collaborators.

Thierry Darnis Thierry Darnis
Global Vice President, Manufacturing & Engineering

Thierry Darnis, brings extensive experience in the management of major manufacturing sites for medical devices, acquired at top-tier global companies. At Medtronic and CR Bard he managed plants pursuing a successful twofold objective of increasing volumes, while optimizing costs. Before joining Biom’up, Thierry Darnis was deputy chief executive officer of Sofradim Production, a subsidiary of Medtronic plc (Dublin, Ireland / Minnesota, USA), and managed its Trevoux plant (340 employees) for more than 12 years. He has a Ph.D. in Life and Health Sciences, specialized in Biomaterials, from the University of Bordeaux II.

Simon Schwaighofer Simon Schwaighofer, MD
Vice President of Sales Europe

Simon is an electronics and biomedical engineer by training and holds an MD from Vienna University. He worked in a startup company for implantable devices where he oversaw clinical and professional education activities, held various local and global sales and business development roles at Medtronic where he also served as a medical director. Simon joined biom’up in September 2016 from Mölnlycke where he worked as general manager in different geographies for both their wound care and surgical divisions. He is responsible for the overall commercial strategy and execution, with a focus on HEMOBLAST™ Bellows, as well as the existing biosurgery portfolio.

Jean-Yves Quentel Jean-Yves Quentel
Chief Financial Officer Group

Jean-Yves Quentel has 25 years of experience as an investor, advisor and director of high technology companies in the USA and in Europe. He acquired experiences in venture capital investment, fundraising, mergers and acquisition in London. In 2010, Jean-Yves joined Atego Group Ltd, a software company for embedded systems as Administration and Finance Group Director where he was also in charge of business development. In 2012, he created Mensia Technologies, a company that produces non-invasive medical devices for the treatment of central nervous system disorders. In December 2017, Jean-Yves joined the Group as Business Development Manager and became Chief Financial Officer in 2018.